The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis

Background. Currently, both of entecavir and lamivudine are effective for patients with HBV-associated acute-on-chronic liver failure (ACLF). However, there is no consensus on the efficacy of entecavir versus lamivudine for patients with HBV-associated ACLF. The aim of the study was to compare the e...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiao Yang, Hang Sun, Qi Liu
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2016/5802674
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832562460006023168
author Jiao Yang
Hang Sun
Qi Liu
author_facet Jiao Yang
Hang Sun
Qi Liu
author_sort Jiao Yang
collection DOAJ
description Background. Currently, both of entecavir and lamivudine are effective for patients with HBV-associated acute-on-chronic liver failure (ACLF). However, there is no consensus on the efficacy of entecavir versus lamivudine for patients with HBV-associated ACLF. The aim of the study was to compare the efficacy and safety of entecavir with that of lamivudine for HBV-associated ACLF patients. Methods. Publications on entecavir versus lamivudine in HBV-associated ACLF patients were comprehensively identified. Odds ratio and mean difference were used to measure the effect. Results. Ten studies, totaling 1254 patients, were eligible. No significant differences between the two drugs presented in the 1-, 2-, 3-, or 6-month survival rates. However, after 12 months of treatment, patients prescribed entecavir had a statistically higher survival rate (p=0.008) and lower total bilirubin (p<0.0001) and alanine aminotransferase (p=0.04) levels compared to patients prescribed lamivudine. More patients achieved HBV negative levels when taking entecavir as measured at 1-, 3-, and 12-month time points and had a lower rate of HBV recurrence. Conclusion. While entecavir and lamivudine are both relatively safe and well tolerated, entecavir was more efficacious in terms of survival rate and clinical improvement in long-term treatment. Further prospective randomized controlled trials are needed to validate these results.
format Article
id doaj-art-36792a2ac6974213b03826ddf5a03591
institution Kabale University
issn 1687-6121
1687-630X
language English
publishDate 2016-01-01
publisher Wiley
record_format Article
series Gastroenterology Research and Practice
spelling doaj-art-36792a2ac6974213b03826ddf5a035912025-02-03T01:22:35ZengWileyGastroenterology Research and Practice1687-61211687-630X2016-01-01201610.1155/2016/58026745802674The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-AnalysisJiao Yang0Hang Sun1Qi Liu2Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Chongqing 400010, ChinaDepartment of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Chongqing 400010, ChinaDepartment of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Chongqing 400010, ChinaBackground. Currently, both of entecavir and lamivudine are effective for patients with HBV-associated acute-on-chronic liver failure (ACLF). However, there is no consensus on the efficacy of entecavir versus lamivudine for patients with HBV-associated ACLF. The aim of the study was to compare the efficacy and safety of entecavir with that of lamivudine for HBV-associated ACLF patients. Methods. Publications on entecavir versus lamivudine in HBV-associated ACLF patients were comprehensively identified. Odds ratio and mean difference were used to measure the effect. Results. Ten studies, totaling 1254 patients, were eligible. No significant differences between the two drugs presented in the 1-, 2-, 3-, or 6-month survival rates. However, after 12 months of treatment, patients prescribed entecavir had a statistically higher survival rate (p=0.008) and lower total bilirubin (p<0.0001) and alanine aminotransferase (p=0.04) levels compared to patients prescribed lamivudine. More patients achieved HBV negative levels when taking entecavir as measured at 1-, 3-, and 12-month time points and had a lower rate of HBV recurrence. Conclusion. While entecavir and lamivudine are both relatively safe and well tolerated, entecavir was more efficacious in terms of survival rate and clinical improvement in long-term treatment. Further prospective randomized controlled trials are needed to validate these results.http://dx.doi.org/10.1155/2016/5802674
spellingShingle Jiao Yang
Hang Sun
Qi Liu
The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis
Gastroenterology Research and Practice
title The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis
title_full The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis
title_fullStr The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis
title_full_unstemmed The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis
title_short The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis
title_sort comparative efficacy and safety of entecavir and lamivudine in patients with hbv associated acute on chronic liver failure a systematic review and meta analysis
url http://dx.doi.org/10.1155/2016/5802674
work_keys_str_mv AT jiaoyang thecomparativeefficacyandsafetyofentecavirandlamivudineinpatientswithhbvassociatedacuteonchronicliverfailureasystematicreviewandmetaanalysis
AT hangsun thecomparativeefficacyandsafetyofentecavirandlamivudineinpatientswithhbvassociatedacuteonchronicliverfailureasystematicreviewandmetaanalysis
AT qiliu thecomparativeefficacyandsafetyofentecavirandlamivudineinpatientswithhbvassociatedacuteonchronicliverfailureasystematicreviewandmetaanalysis
AT jiaoyang comparativeefficacyandsafetyofentecavirandlamivudineinpatientswithhbvassociatedacuteonchronicliverfailureasystematicreviewandmetaanalysis
AT hangsun comparativeefficacyandsafetyofentecavirandlamivudineinpatientswithhbvassociatedacuteonchronicliverfailureasystematicreviewandmetaanalysis
AT qiliu comparativeefficacyandsafetyofentecavirandlamivudineinpatientswithhbvassociatedacuteonchronicliverfailureasystematicreviewandmetaanalysis